Compare Ascendis Pharma A/S (ASND) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs VanEck Vietnam ETF — how do they compare? Ascendis Pharma A/S trades at $255.33 (market cap $16.67B), while VanEck Vietnam ETF trades at $17.8. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| ASND | VNM | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $19.80 |
52-Week Low | $189.74 | $16.34 |
Enterprise Value | $17.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
VNM trades at $17.83, up 1.08% today, with a bullish overall technical signal from indicators. The stock shows mixed technical signals with bearish moving averages but bullish ADX readings, while support and resistance cluster tightly around $17-$18. Recent news highlights Vietnam's economic challenges, including power grid strain and foreign capital outflows from Asian equities, potentially impacting the ETF's holdings.
The outlook is cautious due to Vietnam's macroeconomic headwinds and ETF underperformance, though potential exists from FTSE Russell's EM reclassification. Key risks include regional economic volatility and sector-specific pressures, while institutional sentiment remains watchful amid these developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
